Bromantane

Bromantane at a Glance

Bromantane (brand name Ladasten) is a synthetic adamantane derivative that Russian pharmacology classes as an “actoprotector” — a synthetic adaptogen intended to sustain mental and physical performance under stress without the crash of a classical stimulant ^{7,22Reference 7Oliynyk S · 2012ReviewThe pharmacology of actoprotectors: practical application for improvement of mental and physical performance — reviewView study →Reference 22Todorova V et al. · 2021Systematic reviewPlant adaptogens — history and future perspectives — systematic reviewView study →}. Structurally it belongs to the same diamondoid family as the clinically used drugs amantadine and memantine.

It is fully synthetic with no dietary source, and it is an approved prescription medicine in Russia only — everywhere else it is an unregulated research chemical.

What makes it pharmacologically unusual is that it is not a reuptake blocker in the amphetamine sense. It is only a weak dopamine-transporter inhibitor; its main action is to increase the production of dopamine by switching on transcription of the tyrosine hydroxylase gene. That distinction is not academic — it is why the drug behaves like a slow modulator rather than a stimulant, with effects that build over days and outlast the dosing.

The honest bottom line: there is genuine controlled human evidence for asthenia — including a 728-patient multicentre trial — but essentially all of it is Russian-language, single-region and industry-adjacent, with no independent Western replication. It is also WADA-banned, which is the most concrete risk for anyone competing.

What It’s Used For

Ranked by how well the evidence holds up:

• Asthenia and neurasthenia — the flagship use, with a placebo-controlled RCT plus a 728-patient multicentre trial reporting 76–91% responders.
• Anxiety — a real anxiolytic component, but measured inside the asthenia trials rather than in a dedicated anxiety study.
• Cognitive performance under fatigue — improves performance in tired people, and notably does nothing in untired ones.
• Physical performance — the defining actoprotector claim, resting almost entirely on animal work.
• Parkinson’s non-motor symptoms and depression — a single small trial and preclinical data respectively.

Be sceptical of the general “nootropic” framing. The one study that tested untired healthy men found bromantane did not change their subjective state or core performance ^{6Reference 6Viatleva OA et al. · 2000The neuro- and psychophysiological effects of bromantane (healthy operators, EEG)View study →} — the benefit is specific to a depleted state, not a general cognitive upgrade. The ergogenic reputation is similar: it comes from animal work and, circularly, from the drug’s own doping ban.

How It Works

Bromantane’s mechanism is the most interesting thing about it, and it explains its odd time course.

Rather than blocking dopamine reuptake, it increases dopamine synthesis at the level of gene expression. It raises transcription of tyrosine hydroxylase — the rate-limiting enzyme of dopamine production — partly through CpG demethylation of the TH gene promoter and reduced HDAC1, and it also induces DOPA-decarboxylase ^{9,10Reference 9Vakhitova IuV et al. · 2004AnimalLadasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brainView study →Reference 10Vakhitova IuV et al. · 2006AnimalCytosine demethylation in the tyrosine hydroxylase gene promoter in rat hypothalamus under the aminoadamantane derivative ladastenView study →}. This is an epigenetic, genomic action, not a receptor event.

It does inhibit the dopamine transporter, but only weakly: IC₅₀ ≈ 3.56 µM, against roughly 29 nM for the Russian stimulant sidnocarb ^{11Reference 11Zimin IA et al. · 2010Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarbView study →}. It has no direct agonism or antagonism at D1, D2, D3, 5-HT1A or 5-HT2A receptors — its dopaminergic effect is entirely upstream ^{11Reference 11Zimin IA et al. · 2010Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarbView study →}, with only modest region-specific shifts in serotonin turnover ^{12Reference 12Kudrin VS et al. · 1995AnimalThe effect of bromantane on the dopamin- and serotoninergic systems of the rat brainView study →}.

The anxiolytic half comes from elsewhere: bromantane normalises stress-reduced binding at the benzodiazepine site of the GABA-A receptor, in the same direction as reference anxiolytics ^{13Reference 13Iarkova MA et al. · 2011AnimalAnalysis of the binding capacity of the benzodiazepine site of the GABA-A receptor in mice pretreated with anxiolytics (afobazole, ladasten, noopept)View study →}. It also induces BDNF and NGF via ERK/MAPK signalling ^{14Reference 14Salimgareeva MKh et al. · 2012Mechanisms of action of ladasten: activation of gene expression for neurotrophins (BDNF, NGF) and mitogen-activated kinasesView study →}.

The practical consequence is the important part. TH mRNA roughly doubles 1.5–2 hours after a dose, but the clinical effect appears around day 3 and keeps building — then persists for about a month after the drug is stopped ^{2,9Reference 2Voznesenskaia TG et al. · 2010Clinical trialTreatment of asthenic disorders in patients with psychoautonomic syndrome: multicenter study on efficacy and safety of ladasten (728 patients) — multicenter clinical trialView study →Reference 9Vakhitova IuV et al. · 2004AnimalLadasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brainView study →}. This is not a same-hour stimulant, and escalating the dose chasing an acute effect works against how it was actually studied.

Pharmacology & Research

Bromantane (brand name Ladasten; N-(2-adamantyl)-N-(4-bromophenyl)amine) is a synthetic adamantane derivative classed by Russian pharmacology as an actoprotector — a synthetic adaptogen intended to improve mental and physical performance under stress without the crash of a classical stimulant ^{7Reference 7Oliynyk S · 2012ReviewThe pharmacology of actoprotectors: practical application for improvement of mental and physical performance — reviewView study →}.

Its unusual profile is a combination of mild psychostimulant and anxiolytic actions, and its flagship use is asthenia (chronic fatigue-like states). Mechanistically it is not a reuptake blocker in the amphetamine sense: it is a weak dopamine-transporter inhibitor that acts mainly by up-regulating de novo dopamine synthesis through transcription of the tyrosine hydroxylase gene, including via CpG demethylation of the TH promoter ^{8,9,10,11Reference 8Mikhaylova M et al. · 2007AnimalThe effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in ratsView study →Reference 9Vakhitova IuV et al. · 2004AnimalLadasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brainView study →Reference 10Vakhitova IuV et al. · 2006AnimalCytosine demethylation in the tyrosine hydroxylase gene promoter in rat hypothalamus under the aminoadamantane derivative ladastenView study →Reference 11Zimin IA et al. · 2010Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarbView study →}.

The decision-relevant caveats are unusual: nearly all human efficacy data are Russian-language, single-region, and industry-adjacent, with essentially no independent Western replication; it is an approved prescription medicine in Russia only, an unapproved research chemical everywhere else, and a WADA-prohibited substance in sport.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.

01Asthenia & neurastheniaPromising66%RCT + 728-patient multicenter trial + phase II pilot; all Russian-language, single-region, unreplicated

02AnxietyPromising52%Anxiolytic signal within asthenia RCTs + preclinical GABA-A/open-field data

03Cognitive performance under fatigueShaky44%Small single-dose healthy-volunteer studies; benefit only in the fatigued state

04Physical performanceShaky38%Animal work-capacity + actoprotector class rationale; human ergogenic data thin

05Parkinson non-motor symptomsShaky32%A single small RCT (no accessible abstract)

06Depression (adjuvant)Shaky24%Preclinical mouse data (anti-inflammatory / cytokine) only

Mechanisms

Note: ladasten shows no direct agonism/antagonism at D1/D2/D3 or 5-HT1A/5-HT2A receptors in vitro — its dopaminergic action is upstream, at the level of synthesis and gene expression ^{11Reference 11Zimin IA et al. · 2010Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarbView study →}.

Pharmacokinetics

Bromantane is orally active (human doses 50–100 mg/day; animal mechanistic work at 50 mg/kg p.o.). Its most distinctive PK-PD feature is a slow, genomic mode of action: TH mRNA roughly doubles 1.5–2 h after a single dose, dopamine and L-DOPA accumulate over hours, and — in the large clinical trial — the antiasthenic effect built from day 3 and persisted for a month after the drug was stopped ^{2,9Reference 2Voznesenskaia TG et al. · 2010Clinical trialTreatment of asthenic disorders in patients with psychoautonomic syndrome: multicenter study on efficacy and safety of ladasten (728 patients) — multicenter clinical trialView study →Reference 9Vakhitova IuV et al. · 2004AnimalLadasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brainView study →}. That durability is consistent with a transcriptional/epigenetic mechanism rather than acute reuptake blockade, and it means the drug behaves less like a fast stimulant and more like a slow-onset modulator. A reliable human elimination half-life is not available in accessible English-language literature, so no figure is asserted here.

Clinical trials

Registered/published human trials are almost exclusively Russian, conducted in the 2000s–2010s around the drug’s development and Russian approval; there is little industry or academic trial activity in English-language registries, and the compound is effectively off the Western clinical radar. Beyond the asthenia and Parkinson’s work, the indexed corpus also includes an exploratory trial in irritable bowel syndrome with associated asthenia ^{20Reference 20Uspenskiĭ IuP · 2010Clinical trialProspects for using ladasten preparations in patients with irritable bowel syndrome — clinical trialView study →} — which is better read as another application of the fatigue indication than as a gastrointestinal one. The counts below are approximate, based on the PubMed-indexed corpus.

Last checked: August 2026.

Dietary Sources

Bromantane is a fully synthetic molecule with no dietary source — it does not occur in food and cannot be obtained from diet. It is a member of the adamantane (“diamondoid”) drug family, related to memantine and amantadine, and is manufactured synthetically: the core is an N-(2-adamantyl)-N-(para-bromophenyl)amine, typically assembled by coupling a 2-adamantyl group to a 4-bromoaniline (reductive-amination chemistry). There is therefore no “eat more of X” alternative to supplementation, and no food-versus-supplement bioavailability trade-off to weigh.

Dosage

Bromantane is not a nutrient, so it has no RDA/AI and no Tolerable Upper Intake Level. The only human dosing evidence comes from Russian clinical trials in asthenia:

Practical notes: the effect is slow-onset and cumulative — in the large trial the antiasthenic benefit appeared around day 3 and continued to build, then persisted for about a month after stopping ^{2Reference 2Voznesenskaia TG et al. · 2010Clinical trialTreatment of asthenic disorders in patients with psychoautonomic syndrome: multicenter study on efficacy and safety of ladasten (728 patients) — multicenter clinical trialView study →}. This is a drug that works over days, not a same-hour stimulant, so escalating the dose chasing an acute “kick” runs contrary to how it was studied. These are doses studied in research, not a personal recommendation, and outside Russia the compound is an unapproved research chemical whose real content and purity are unverified.

Safety

Bromantane’s acute toxicity is genuinely low; its real risks are regulatory and contextual rather than pharmacological.

Safety at a Glance

⚠️ Moderate toxicityDrug interactions

• Low acute toxicity in animals. A wide gap between behaviourally active doses (30–300 mg/kg) and suppressive/toxic ones (600–9,600 mg/kg) ^{16,17Reference 16Bugaeva LI et al. · 2000An acute toxicity study of bromantaneView study →Reference 17Iezhitsa IN et al. · 2002Toxic effect of single treatment with bromantane on neurological status of experimental animalsView study →}.
• No withdrawal syndrome. Stopping after 28-day courses produced none, arguing against physical dependence ^{1,2Reference 1Neznamov GG et al. · 2009RCTLadasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo) — randomised controlled trialView study →Reference 2Voznesenskaia TG et al. · 2010Clinical trialTreatment of asthenic disorders in patients with psychoautonomic syndrome: multicenter study on efficacy and safety of ladasten (728 patients) — multicenter clinical trialView study →}.
• ~3% adverse-event rate in the 728-patient trial, 0.8% discontinuation, no serious events ^{2Reference 2Voznesenskaia TG et al. · 2010Clinical trialTreatment of asthenic disorders in patients with psychoautonomic syndrome: multicenter study on efficacy and safety of ladasten (728 patients) — multicenter clinical trialView study →}.
• WADA-prohibited and implicated in doping cases ^{18Reference 18Burnat P · 1997Bromontan, a new doping agent — letterView study →} — a competition-ending finding for any athlete.
• A prescription medicine in Russia only. Everywhere else it is an unregulated research chemical of unverified identity and purity.
• Interactions unstudied. Plausible caution with other dopaminergic or stimulant drugs; no dedicated human interaction studies exist.

Full Safety & Interactions Detail

In animals, single-dose bromantane has low acute toxicity, with a wide gap between behaviourally active doses (30–300 mg/kg, stimulating) and suppressive/toxic doses (600–9,600 mg/kg) ^{16,17Reference 16Bugaeva LI et al. · 2000An acute toxicity study of bromantaneView study →Reference 17Iezhitsa IN et al. · 2002Toxic effect of single treatment with bromantane on neurological status of experimental animalsView study →}.

Toxic-range effects in animals were driven by cholinergic actions and included mydriasis, altered respiration, and hypothermia ^{16,17Reference 16Bugaeva LI et al. · 2000An acute toxicity study of bromantaneView study →Reference 17Iezhitsa IN et al. · 2002Toxic effect of single treatment with bromantane on neurological status of experimental animalsView study →}.

In the 728-patient human trial, adverse effects occurred in only ~3% of patients, discontinuation in 0.8%, with no serious adverse events reported, and — importantly — no withdrawal syndrome after stopping, arguing against physical dependence ^{1,2Reference 1Neznamov GG et al. · 2009RCTLadasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo) — randomised controlled trialView study →Reference 2Voznesenskaia TG et al. · 2010Clinical trialTreatment of asthenic disorders in patients with psychoautonomic syndrome: multicenter study on efficacy and safety of ladasten (728 patients) — multicenter clinical trialView study →}.

The real safety issues are not acute toxicity but context:

1. it is a prescription medicine in Russia only and an unregulated research chemical elsewhere, so purchased material has unverified identity and purity;
2. it is a WADA-prohibited substance and has featured in doping cases — a concrete, verifiable risk for any competitive athlete ^{18Reference 18Burnat P · 1997Bromontan, a new doping agent — letterView study →};
3. as a dopaminergic agent, plausible caution applies with other dopaminergic or stimulant drugs, though specific human drug-interaction studies are lacking.

Scope disclosure. Interactions assessed? Partially — mechanistic plausibility with dopaminergic/stimulant drugs is noted, but no dedicated human drug-interaction studies were found. Pregnancy/lactation assessed? No human data — animal reproductive studies exist but human safety is not established. Upper limit established? No. Long-term human safety of bromantane is genuinely not characterized.

Pregnancy & Lactation

⚠ Avoid in pregnancy⚠ Avoid while breastfeeding

Avoid. Human safety in pregnancy and lactation has not been established in accessible literature. Some Russian reproductive-toxicity animal studies exist but do not substitute for human data, and there is no basis to consider bromantane safe during pregnancy or breastfeeding. It should not be used.

Mechanistic and class relatives: bemitil (bemethyl), the other principal actoprotector ^{7Reference 7Oliynyk S · 2012ReviewThe pharmacology of actoprotectors: practical application for improvement of mental and physical performance — reviewView study →}; sidnocarb (sydnocarb), the Russian psychostimulant used as comparator in several of the mechanistic studies and a far stronger DAT inhibitor ^{11Reference 11Zimin IA et al. · 2010Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarbView study →}; amantadine and memantine, the clinically used adamantane-family drugs sharing the diamondoid scaffold ^{8Reference 8Mikhaylova M et al. · 2007AnimalThe effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in ratsView study →}; and afobazole and noopept, the Russian anxiolytic/nootropic agents studied in the same GABA-A benzodiazepine-site work ^{13Reference 13Iarkova MA et al. · 2011AnimalAnalysis of the binding capacity of the benzodiazepine site of the GABA-A receptor in mice pretreated with anxiolytics (afobazole, ladasten, noopept)View study →}.

References

1. Neznamov GG, Siuniakov SA, et al. (2009). Ladasten, the new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia (results of the comparative clinical study with placebo) — randomised controlled trial. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. https://pubmed.ncbi.nlm.nih.gov/19491814/
2. Voznesenskaia TG, et al. (2010). Treatment of asthenic disorders in patients with psychoautonomic syndrome: multicenter study on efficacy and safety of ladasten (728 patients) — multicenter clinical trial. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. https://pubmed.ncbi.nlm.nih.gov/21322821/
3. Siuniakov SA, et al. (2006). Pilot clinical trial of ladasten — phase II clinical trial. Eksperimental’naia i Klinicheskaia Farmakologiia. https://pubmed.ncbi.nlm.nih.gov/16995430/
4. Mametova LE, et al. (2011). Self-evaluation of single test doses and objective indices of ladasten vs. placebo efficacy in neurasthenic patients — randomised controlled trial. Eksperimental’naia i Klinicheskaia Farmakologiia. https://pubmed.ncbi.nlm.nih.gov/22288153/
5. Bogdan NG, Kolotilinskaia NV, Iarkova MA, et al. (2009). Effect of ladasten on the psychophysiological parameters of healthy volunteers. Eksperimental’naia i Klinicheskaia Farmakologiia. https://pubmed.ncbi.nlm.nih.gov/19642584/
6. Viatleva OA, Barchukov VG, Morozov IS, et al. (2000). The neuro- and psychophysiological effects of bromantane (healthy operators, EEG). Voen Med Zh. https://pubmed.ncbi.nlm.nih.gov/10998997/
7. Oliynyk S, Oh S. (2012). The pharmacology of actoprotectors: practical application for improvement of mental and physical performance — review. Biomolecules & Therapeutics. https://pubmed.ncbi.nlm.nih.gov/24009833/
8. Mikhaylova M, Vakhitova JV, Yamidanov RS, et al. (2007). The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats. Neuropharmacology. https://pubmed.ncbi.nlm.nih.gov/17854844/
9. Vakhitova IuV, Iamidanov RS, Seredinin SB, et al. (2004). Ladasten induces the expression of genes regulating dopamine biosynthesis in various structures of rat brain. Eksp Klin Farmakol. https://pubmed.ncbi.nlm.nih.gov/15500036/
10. Vakhitova IuV, Sadovnikov SV, Iamidanov RS, et al. (2006). Cytosine demethylation in the tyrosine hydroxylase gene promoter in rat hypothalamus under the aminoadamantane derivative ladasten. Genetika. https://pubmed.ncbi.nlm.nih.gov/16915929/
11. Zimin IA, Abaimov DA, Budygin EA, et al. (2010). Role of the brain dopaminergic and serotoninergic systems in psychopharmacological effects of ladasten and sydnocarb. Eksperimental’naia i Klinicheskaia Farmakologiia. https://pubmed.ncbi.nlm.nih.gov/20369592/
12. Kudrin VS, Sergeeva SA, Krasnykh LM, et al. (1995). The effect of bromantane on the dopamin- and serotoninergic systems of the rat brain. Eksperimental’naia i Klinicheskaia Farmakologiia. https://pubmed.ncbi.nlm.nih.gov/7580761/
13. Iarkova MA, et al. (2011). Analysis of the binding capacity of the benzodiazepine site of the GABA-A receptor in mice pretreated with anxiolytics (afobazole, ladasten, noopept). Eksperimental’naia i Klinicheskaia Farmakologiia. https://pubmed.ncbi.nlm.nih.gov/22232906/
14. Salimgareeva MKh, Yamidanov RS, Vakhitova YV, et al. (2012). Mechanisms of action of ladasten: activation of gene expression for neurotrophins (BDNF, NGF) and mitogen-activated kinases. Bulletin of Experimental Biology and Medicine. https://pubmed.ncbi.nlm.nih.gov/22803074/
15. Tallerova AV, et al. (2011). Effect of ladasten on cytokine markers of inflammation (TNF-α, IL-6) and behavior of mice with experimental depression-like syndrome. Bulletin of Experimental Biology and Medicine. https://pubmed.ncbi.nlm.nih.gov/22803040/
16. Bugaeva LI, Verovskiĭ VE, Iezhitsa IN, et al. (2000). An acute toxicity study of bromantane. Eksperimental’naia i Klinicheskaia Farmakologiia. https://pubmed.ncbi.nlm.nih.gov/10763112/
17. Iezhitsa IN, Spasov AA, Bugaeva LI, et al. (2002). Toxic effect of single treatment with bromantane on neurological status of experimental animals. Bulletin of Experimental Biology and Medicine. https://pubmed.ncbi.nlm.nih.gov/12124651/
18. Burnat P, Payen A. (1997). Bromontan, a new doping agent — letter. Lancet. https://pubmed.ncbi.nlm.nih.gov/9314900/
19. Sarycheva TN, Rybak VA, Kurushina OV, et al. (2011). Ladasten in the management of non-motor symptoms of Parkinson’s disease — randomised controlled trial. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. https://pubmed.ncbi.nlm.nih.gov/21434470/
20. Uspenskiĭ IuP, Fominykh IuA (2010). Prospects for using ladasten preparations in patients with irritable bowel syndrome — clinical trial. Eksperimental’naia i Klinicheskaia Gastroenterologiia. https://pubmed.ncbi.nlm.nih.gov/21434378/
21. Levina MN, et al. (2005). Psychotropic effects of sidnocarb and ladasten in inbred mice with different reaction to emotional stress. Bulletin of Experimental Biology and Medicine. https://pubmed.ncbi.nlm.nih.gov/16027847/
22. Todorova V, Ivanov K, Delattre C, et al. (2021). Plant adaptogens — history and future perspectives — systematic review. Nutrients. https://pubmed.ncbi.nlm.nih.gov/34445021/
23. Morozov IS, Kleĭmenova NN (1998). The effect of bromantane on the physical work capacity of laboratory animals. Eksperimental’naia i Klinicheskaia Farmakologiia. https://pubmed.ncbi.nlm.nih.gov/9929819/

View all 23 references▾